全文获取类型
收费全文 | 1285篇 |
免费 | 107篇 |
国内免费 | 8篇 |
专业分类
耳鼻咽喉 | 9篇 |
儿科学 | 65篇 |
妇产科学 | 9篇 |
基础医学 | 123篇 |
口腔科学 | 38篇 |
临床医学 | 211篇 |
内科学 | 242篇 |
皮肤病学 | 31篇 |
神经病学 | 72篇 |
特种医学 | 254篇 |
外科学 | 112篇 |
综合类 | 39篇 |
一般理论 | 4篇 |
预防医学 | 74篇 |
眼科学 | 11篇 |
药学 | 54篇 |
中国医学 | 5篇 |
肿瘤学 | 47篇 |
出版年
2023年 | 10篇 |
2022年 | 6篇 |
2021年 | 13篇 |
2020年 | 12篇 |
2019年 | 13篇 |
2018年 | 37篇 |
2017年 | 22篇 |
2016年 | 26篇 |
2015年 | 27篇 |
2014年 | 39篇 |
2013年 | 35篇 |
2012年 | 39篇 |
2011年 | 41篇 |
2010年 | 46篇 |
2009年 | 64篇 |
2008年 | 31篇 |
2007年 | 17篇 |
2006年 | 26篇 |
2005年 | 17篇 |
2004年 | 17篇 |
2003年 | 26篇 |
2002年 | 31篇 |
2001年 | 26篇 |
2000年 | 26篇 |
1999年 | 35篇 |
1998年 | 57篇 |
1997年 | 56篇 |
1996年 | 69篇 |
1995年 | 49篇 |
1994年 | 44篇 |
1993年 | 52篇 |
1992年 | 21篇 |
1991年 | 13篇 |
1990年 | 20篇 |
1989年 | 40篇 |
1988年 | 33篇 |
1987年 | 41篇 |
1986年 | 41篇 |
1985年 | 31篇 |
1984年 | 16篇 |
1983年 | 11篇 |
1982年 | 25篇 |
1981年 | 16篇 |
1980年 | 11篇 |
1979年 | 6篇 |
1978年 | 9篇 |
1977年 | 14篇 |
1976年 | 14篇 |
1975年 | 13篇 |
1967年 | 3篇 |
排序方式: 共有1400条查询结果,搜索用时 15 毫秒
1.
ME BURGE AM JOSHUA CM McNEIL R HUI MJ BOYER R ABRAHAM 《Asia-Pacific Journal of Clinical Oncology》2005,1(1):47-52
Background: Pemetrexed and cisplatin have recently been shown to significantly improve survival compared with cisplatin alone. However, there are only limited data reflecting teaching hospital experience outside a clinical trial. Pemetrexed has only been available in Australia on a restricted basis since 2002. We reviewed our experience of patients treated on the Australian ‘Special Access Scheme’ at three major thoracic oncology units. Methods: Charts were reviewed for all patients enrolled on the scheme. Data was extracted on age, World Health Organization (WHO) performance status, histology, prior therapy, time from diagnosis to starting pemetrexed, chemotherapy (pemetrexed alone or with a platinum), cycle number, response rate, actuarial progression‐free and overall survival. Doses were cisplatin 75 mg/m2 or carboplatin AUC = 5 and pemetrexed 500 mg/m2 every 21 days. Results: 52 patients (32 male and 20 female) were reviewed. Median age was 58 years and 88% were WHO 0–1. Histology included 54% epithelial, 17% biphasic (epithelial and sarcomatoid) and 21% undefined. The median time from diagnosis to administration of pemetrexed was 145 days. Sixty‐five percent had minimal surgical intervention with video assisted thoracoscopy, pleurodesis and biopsy, while 19% had received prior palliative radiation. Seventy‐one percent were chemotherapy naïve, the remaining 29% having received previous platinum and/or gemcitabine regimens. Twenty‐three percent had pemetrexed alone, 35% in combination with carboplatin and 42% with cisplatin. The median number of cycles was 4 (range 1–13). The response rate was 33%. No toxicity was observed in 20% grade 3–4 toxicity in 10% (majority nausea/vomiting). The median progression‐free and overall survival times from starting pemetrexed were 184 days and 298 days, respectively. Conclusions: Pemetrexed‐based regimens are safe and effective in a community setting in malignant mesothelioma. 相似文献
2.
3.
4.
5.
J R Bishop J W Moul S A Sihelnik D S Peppas T S Gormley D G McLeod 《The Journal of urology》1992,147(2):386-388
We report an 18-month prospective study of 90 patients undergoing penile prosthesis implantation to evaluate a possible cause-and-effect relationship between degree of diabetic control and the risk of infection complicating the operation. Long-term diabetic control was objectively evaluated by measurement of the glycosylated hemoglobin of the patient, which is known to provide an objective value for degree of control for the preceding 60 to 90 days. Of 90 patients 5 (5.5%) had a periprosthetic infection requiring explantation and all infections occurred in the 32 diabetics (36%) in the population (p less than 0.009). Of the 32 diabetics 13 (41.1%) were poorly controlled with time as demonstrated by a glycosylated hemoglobin level of greater than 11.5% and 4 of the infections occurred in this group. Of the 19 remaining controlled diabetics (glycosylated hemoglobin level less than 11.5%) only 1 infection occurred. Therefore, infection occurred in 31% of the poorly controlled versus 5% of the adequately controlled patients (p less than 0.0003). Measurement of glycosylated hemoglobin values appears to be a useful tool to evaluate diabetic patients before implantation of a penile prosthesis. Patients with a glycosylated hemoglobin level of 11.5% or greater should be more optimally controlled before undergoing implantation in an effort to avoid infectious complications. 相似文献
6.
7.
8.
The cytotoxic reactivity of 18 predefined class I HLA serum antibodies was compared with that of antibody preparations containing anticoagulants. ACD-A, EDTA, 4% citrate and heparin plasmas all showed lower cytotoxicity than serum antibodies. Recalcification of both platelet-rich and platelet-poor ACD-A plasma did not fully restore the antibody reactivity, suggesting a detrimental effect of calcium chelation. This effect was exclusive of volume or of any platelet or plasma protein involvement. The changes in pH contributed to the lower reactivity and to the increased lympholytic effect, whereas adjusting the pH toward the serum value improved the reactivity. Heat-inactivated antibodies showed only a slightly reduced cytotoxicity. Heparin had the least effect of all anticoagulants on the reactivity, although in heparin there was a definite dose-dependent decline in cytotoxic titer which was probably related to anticomplementary activity. Calcium chelators, such as EDTA and citrate, showed marked cytotoxic inhibition at half the usual complement concentration. This effect was more pronounced when the anticoagulant and lymphocytes were incubated prior to cytotoxicity testing. At the complement concentrations used, the inhibitory effects of the citrate anticoagulants appeared to be primarily calcium-related. Inhibition tests, serial titrations and testing of varying calcium concentrations confirmed the superiority of serum as antibody source. 相似文献
9.
10.